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A cross-sectional survey of all patients aged 30–65 in four general practices within one Local Health Care Co-operative in Fife,
Scotland was undertaken to measure the prevalence of family history of colorectal, breast and ovarian cancer. A total of 7619
patients aged 30–65 responded to a postal questionnaire (response rate 59%). In all, 17% of respondents (1324, 95% Cl 16–18%)
reported a relative affected by colorectal, breast or ovarian cancer. Of those, 6% (78, 95% CI 5–7%) met the Scottish guidelines for
referral for genetics counselling. In all, 2% (24, 95% CI 1–3%) of all individuals with an affected relative had received genetic
counselling and risk assessment. Of these, 25% (6, 95% CI 8–42%) met the moderate- or high-risk criteria for developing a cancer. In
conclusion, the number of patients who are at a significantly increased risk of cancer on the basis of a family history is small
(approximately 10 per General Practitioner (GP) list). It is therefore unrealistic to expect GPs to develop expertise in genetic risk
estimation. A simple family history chart or pedigree is one way that a GP can, within the constraints of a GP consultation, determine
which patients should be reassured and which referred to the local cancer genetic clinic.
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Cancer is one of the three health priorities of the National Health
Service in Scotland (NHSiS) (Scottish Office, 1998). Local Health
Care Co-operatives (LHCCs) were created in Scotland in 1998 to
provide local management of services, and are made up of
representatives of local general practices and local service groups
and patient groups (Scottish Office, 1998). They have been charged
with measuring health needs within their communities to reflect
the clinical priorities for the area and to support the development
of population-wide approaches to health improvement and disease
prevention (Scottish Office, 1997).
Cancer genetics is the fastest growing area of clinical genetics
(Wonderling et al, 2001). In Scotland, the four Regional Genetic
Centres co-ordinate accurate risk assessment to ensure that
individuals referred for screening investigations such as mammo-
graphy and colonoscopy fulfil the national criteria laid down by
the Cancer Genetic subgroup of the Scottish Cancer Group
(Table 1). The lifetime risks for breast, colon and ovarian cancers
in the general population are approximately one in 10, one in 60
and one in 90, respectively (ISD, 1998). All general practitioners
(GPs) will, therefore, have patients with a relative with one of these
cancers. An unknown proportion of these patients are likely to
seek counselling and advice regarding their risk of developing
cancer (Biesecker et al, 1993). The relative risk associated with a
family history of these cancers has been widely reported (St John
et al, 1993; Slattery and Kerber, 1994; Pharoah et al, 1997). The
challenge is to identify the minority at significantly increased
genetic risk of developing cancer while reassuring the majority
whose family history does not indicate a likely increased cancer
risk above that of the general population.
A major problem in planning cancer genetic services is that it is
not known as to what proportion of the population fit into the
various cancer genetic risk categories. The Scottish Office report
‘Cancer Genetics Services in Scotland’ (Haites, 2000) recognised
that ‘at present there is no means of identifying the total
population who have a family history which places them at a
significantly increased risk of developing breast, colorectal or
ovarian cancer’. The report also noted that the uncertainty of these
estimates makes it impossible to predict future costs for the
provision of a risk estimation and screening service.
Risk estimation is based on the number of affected individuals
within the family, the pattern of cancers and the age of onset of
cancer. It is therefore necessary for the clinician to take a careful
family history. This process is time-consuming and many GPs are
unsure of their ability to obtain an accurate family tree and assess
genetic risk (Fry et al, 1999). Pre-clinical family history
questionnaires have been used extensively by genetic departments.
This study was designed to evaluate how a similar questionnaire
would be addressed by a general practice population and whether
such a questionnaire might provide data in a form to facilitate GP
cancer genetic risk estimation.
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sWe report the results of a cross-sectional survey conducted
between May 1999 and October 2000 of patients in General
Practice aged between 30 and 65 years to assess the prevalence of a
significant family history of colorectal, breast, or ovarian cancer
and to identify the number of individuals with a family history that
had been referred onto the Clinical Genetic Service. Ethical
approval for the study was granted by the Fife Local Research
Ethics Committee.
PARTICIPANTS AND METHODS
A postal survey of all patients aged 30–65 years from four general
medical practices covering over 99% of the population within one
LHCC in Fife, Scotland was undertaken using a cancer family
history questionnaire that had been developed and evaluated by a
Cambridge-based research team (Leggat et al, 1999). The
questionnaire was adapted to determine whether the patients
had any concerns regarding their own risk of developing cancer
and, if so, whether they had ever been referred to a cancer genetic
specialist or had received any form of genetic counselling
(questionnaire available online at http://137.195.14.43/cgi-bin/
WebObjects/genisys.woa/wa/showDoc?docid¼208).
Patients were asked if they had any family members (grand-
parents, aunts, uncles, father, mother, brothers, sisters and
children) who had had colorectal, breast or ovarian cancer and
the age at which these cancers were diagnosed. Those with no
affected relatives were requested to return the questionnaire at this
point. Those with a family member affected were asked to
complete a detailed family history including relationship to the
affected individual, site of cancer and age at and date of diagnosis.
In all, 305 randomly selected participants reporting a family
history of cancer (23% of total) were interviewed by telephone
(n¼254) or in person by a genetic nurse (n¼51) to check the
consistency of the information collected via the postal survey. A
fieldworker telephoned 101 of those reporting no family history to
confirm that there was no family history of colorectal breast or
ovarian cancer in their families.
RESULTS
A total of 13155 questionnaires were mailed, of which 5535 were
excluded from the study; 281 were returned address unknown and
5254 were not returned by the patient. In all, 7620 (3386 males,
4234 females) were completed and returned (Figure 1). The overall
response rate was 59%. A total of 1396 (18%, 95% CI 17–19%)
responders reported a family history of cancer. When checked by a
genetics nurse, 72 questionnaires reported relatives with a history
of cancers at other sites and were excluded from any further
analysis. In all, 17% of respondents (1324, 95% Cl 16–18%)
therefore identified themselves as having a history of colorectal,
breast, or ovarian cancer in a first- or second-degree relative. Of
these, 918 were females and 375 males. Some respondents reported
a family history of more than one of these cancers. In total, 78
respondents with a family history were classified as being at
medium or high risk of developing colorectal, breast, or ovarian
cancer, and thus met the guidelines for referral to cancer genetics
services in Scotland for risk assessment (Haites, 2000). This
represents approximately 6% (95% CI 5–7%) of all respondents
reporting a family history of cancer.
Colorectal cancer
In all, 31 respondents reporting a family history of colorectal
cancer met the national guidelines for referral for risk assessment,
11 males and 20 females, that is, 5% (95% CI 3–7%) of those
reporting a family history of colorectal cancer and 2% (95% CI 1–
3%) reporting a history of any of the three cancers or 0.41% (95%
CI 0.26–0.55%) of the population surveyed.
Table 1 The Cancer Genetic Sub-committee family history criteria for enrolment in a screening programme for breast, ovarian or colorectal cancer
Breast
Moderate risk
One first-degree relative with bilateral breast cancer
One first-degree relative with breast cancer diagnosed under age 40 years or one first-degree male relative with breast cancer diagnosed at any age
Two first- or first- and second-degree relatives with breast cancer diagnosed under age 60 years and/or ovarian cancer at any age on the same side of the family
Three first- or second-degree relatives with breast or ovarian cancer on the same side of the family (always one first-degree relative unless history is via father)
High risk
An individual with BRCA1 or BRCA2 mutations or other known predisposing gene mutations or the untested first-degree relative of a mutation carrier
One first-degree relative (or second-degree relative via intervening male relative) in a family with four or more relatives affected with breast cancer or ovarian cancer
in three generations
One first-degree relative (or second degree via father) with breast and ovarian cancer
Ovarian
Moderate risk
Two or more first- or first- and second-degree relatives with ovarian cancer
Two first- or first- and second-degree relatives with ovarian cancer at any age and breast cancer diagnosed under 50 years
One ovarian cancer and two breast cancers diagnosed less than 60 years on the same side of the family in first-degree relatives or second degree via a male
Two first- or second-degree relatives with colorectal cancer and/or endometrial cancer and one with ovarian cancer one affected relative with ovarian cancer and
HNPCC family history
High risk
An individual with BRCA1 or BRCA2 mutations or other known predisposing gene mutations or her untested female relatives.
First-degree relative with breast and ovarian cancer
Bowel
Moderate risk
One first-degree relative with colorectal cancer under age 45 years
Two individuals affected with colorectal cancer (one less than 55 years) who are first-degree relatives of each other and one a first-degree relative of the consultant
Three affected family members with colorectal or endometrial cancer who are first-degree relatives of each other and one a first-degree relative of the consultant
High risk
An individual with a mutation in one of the mismatch repair genes or their untested first-degree relatives
A family history compatible with HNPCC according to Amsterdam or modified Amsterdam criteria
Individuals are judged to be at low risk if their family history does not meet the moderate risk criteria for screening.
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In all, 27 of the female respondents met national guidelines for
referral for risk assessment for breast cancer only, that is, 3% (95%
CI 2–4%) of all female respondents reporting a family history of
cancer or 0.64% (95% CI 0.40–0.88%) of the total female
population surveyed.
Ovarian cancer
Two female respondents met the national guidelines for referral
for risk assessment for ovarian cancer only, that is, 0.2% (95%
CI 0–0.5%) of all females reporting a family history of cancer
or 0.05% (95% CI 0–0.1%) of the total female population
surveyed.
Breast and ovarian cancer
In all, 18 female respondents met the national guidelines for
referral for risk assessment, that is, 2% (95% CI 1–3%) of
all female respondents reporting a family history of cancer or
0.43% (95% CI 0.22–0.62%) of the total female population
surveyed.
Interviews of re-contacted participants
A validation study was undertaken in order to assess the
consistency of this information. In all, 352 patients reporting a
family history of cancer were randomly selected and asked to
discuss their history with a genetic nurse either face to face or by
telephone. Of these, 305 (87%) responded and their family history
was verbally confirmed. Of these, 17 (6%, 95% CI 3–8%) were
assessed to be at a moderate to high risk of developing colorectal
cancer and thus met the national criteria for referral for risk
assessment, 28 (9%, 98% CI 6–12%) met the referral criteria for
breast cancer and three (1%, 95% CI 0–2%) for ovarian cancer.
As a result of this group being interviewed by the genetic nurse,
the risk of 21 (7%, 95% CI 4–10%) of the respondents was altered.
The estimated risk of one or more of the three cancers was
increased for 16 of the respondents, although in six cases it was
difficult to verify the risk due to incomplete information, for
example, age of diagnosis of cancer in relative. For five
respondents, the estimated risk of cancer was reduced. Only four
(4%, 95% CI 0.2–8%) of the 101 respondents who originally
reported no family history of breast, ovarian or colorectal cancer
in the family history form subsequently mentioned a family history
on interview with a fieldworker. All four were assessed to be at low
risk of developing cancer.
Questionnaires sent out (n = 13,155) 
Completed questionnaires (n = 7620) 
Positive family history of cancer 
reported (n = 1396 families)
Excluded (n = 5535) 
-  Returned address unknown (n = 281) 
-  No reply (n = 5254) 
Excluded (n = 72) 
-  Cancer site other than breast, bowel or colorectal
Number of relevant cancers reported
(n = 1666) 
Colorectal cancer any
relative (n = 689) 
Breast cancer any
relative (n = 735) 
Ovarian cancer any
relative (n = 242) 
Colorectal cancer first
or second degree
relative (n = 603)  
High risk (n = 4) 
Moderate risk (n = 27) 
Low risk (n = 572) 
Breast cancer first or
second degree 
relative (n = 689) 
Ovarian cancer first or
second degree 
relative (n = 213) 
High risk (n = 12)
Moderate risk (n = 33)
Low risk (n = 644) 
High risk (n = 10) 
Moderate risk (n = 10) 
Low risk (n = 193) 
*
** ** **
*  Some respondents reported more than one relevant cancer 
** Risk to the responder of developing cancer according to the Cancer Genetic Sub-committee 
    guidelines. A total of, 18 women at moderate or high risk of breast and ovarian cancer are represented 
    in both categories 
Figure 1 Flow diagram of response and results of a survey to estimate the prevalence of a family history of selected cancers in a Scottish population
surveyed in 1999–2000.
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In all, 15% of respondents who reported a positive family history
of these cancers had discussed their concerns with their GP,
the great majority during the last 3 years. Out of these respondents,
86% (and 87% of the 30 respondents found to be at moderate
or high risk) had raised the issue themselves (rather than their
GP asking them about the family history of cancer). In all, 10%
of respondents reporting any family history of cancer (and 22%
of those at moderate/high risk) had been referred to a
specialist to discuss their risk of cancer and 2% (25% of those
at moderate/high risk) had received genetic counselling in the
past.
Workload implications for GPs and cancer genetics clinics
Using these results to estimate workload for GPs and cancer
genetic clinics in the rest of Scotland, the following figures are
obtained:
Potentially, only one in 14 patients attending a GP with a
positive family history of cancer needs to be referred to regional
cancer genetics services for further risk assessment.
DISCUSSION
A valid response rate of 59% was achieved for the postal
questionnaire used in this study. This is considerably higher than
that in a previously published study using a similar questionnaire
where the response rate was 29% (Leggat et al, 1999). Possible
explanations for this high response rate to the questionnaire
include: the study was led by the principal GP of one of
the participating general practices and was thus well known to
most patients; a press release publicising the study was issued
prior to mailing; one reminder was sent out to nonresponders 2
weeks after mailing the questionnaire; and a colorectal cancer
screening study had recently been undertaken in one of the four
participating GP practices. When compared with the nonrespon-
ders, the responders were significantly older (mean age 48 years vs
44 years), similar to that reported in the previous study which
evaluated the family history of cancer questionnaire.
9 The study
made no allowance for multiple sampling of the same family, but
the aim was to assess the burden of cancer genetics in a GP
practice. Males with a family history of breast or ovarian cancer
were assessed as low risk, as no clinical screening is indicated for
them.
We have recently shown in Scotland that such reports of a
positive family history of cancer are rarely incorrect but may
substantially underestimate the true prevalence of a history of
cancer in relatives, especially among second-degree relatives, when
compared to cancer registry records (Mitchell et al, 2004). We only
attempted to ‘validate’ a sample of positive reports of family
history of cancer in this study. It is likely that a study which also
involved an analysis of cancer registry records of all relatives
would yield a higher estimate for the family history of cancer.
Thus, the prevalence of family history of cancer in this study can
be considered to represent a minimum estimate. Nevertheless,
patients make decisions about seeking advice about their cancer
risk based on their family history as they perceive it and so that
data presented in this report are important in seeking to plan
services for these patients.
It is interesting to note the higher incidence of moderate- or
high-risk family histories in the subgroup of participants that
agreed to be interviewed. This may reflect a greater interest in
discussing their situation in the moderate- and high-risk groups.
Prior to the study, it was anticipated that some respondents
might experience anxiety concerning their own risk of cancer as a
result of completing the family history questionnaire. Participants
were invited to voice their anxieties by phone with the study team
who could then arrange an appointment with a genetic nurse.
However, it was only necessary for the genetic nurse to contact
two respondents in relation to this issue and she was able to
provide advice and reassurance in both cases. Discussion with
GPs in the practices involved revealed no contact with patients
worried by the results of the study. Many of the respondents
did admit to worries about their family history when interviewed,
but had not taken advantage of genetic counselling. In fact, those
at the greatest risk were the ones who reported least use of the
service.
The majority of questionnaires were completed correctly and
many respondents included a great deal of information about their
family history of cancer, sometimes involving obtaining details
from family members living abroad. For GPs faced with patients
consulting with concerns about their family history, a suitable
response would therefore be to ask the patient to complete a
similar family history form and to rely on this in making a decision
as to whether or not to refer the patient to the local cancer genetics
clinic.
Cancer genetics referral guidelines are quite complex. Therefore,
computer programmes have been developed based on referral
guidelines to support the decision-making by GPs. However, as
GPs will see only a few patients a year, acquiring all of the skills
necessary for genetic counselling or to operate such programmes
may be unlikely to be accorded a high priority. In addition, newly
acquired skills following training are likely to degrade over time
without frequent reinforcement. We suggest that GPs could
use a questionnaire to collect information and then pass it on to
the local genetic nurse, primary care genetic clinician or cancer
centre for a rapid assessment as to whether further action should
be taken.
The number of patients seeking genetic counselling has
increased sharply over the last few years (Wonderling et al,
2001). This study has shown that only about one in 14 patients
attending a GP with a positive family history of cancer needs to be
referred to regional cancer genetics services for further risk
assessment. The importance of the gate-keeping role of the GP is
likely to increase in future. Our experience gained during the
course of this study suggests that this role might be facilitated by
the use of a self-completion family history form in general practice.
Information collected by this means tallies closely with that
obtained from interviews with trained genetic nurses and permit
accurate risk assessments which can guide referral decisions.
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Average caseload of a Scottish GP – 1700 patients
Average number of patients aged 30–65 years – 830 patients
Number with any positive family history (estimate) – 140 patients
Number who had discussed family history with GP – 21 patients
Number meeting referral guidelines (estimate) – 10 patients
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